TWEAK R/TNFRSF12 Antibody

Recombinant Human TWEAK R/TNFRSF12 Fc Chimera (Catalog # 1199‑TW) inhibits Recombinant Human TWEAK/TNFSF12 (Catalog # 1090‑TW) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human TWEAK/TNFSF12 (20 ng/mL) activity elicited by Recombinant Human TWEAK R/TNFRSF12 Fc Chimera (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TWEAK R/TNFRSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1199). The ND50 is typically 0.3-1.2 µg/mL.

Expression of TWEAK and Fn14 in renal biopsies from IgAN patients was examine. Immunohistochemistry for both TWEAK (A, B) and Fn14 (D, E) were detected in glomerular crescents (the areas delineated by the squares). In the controls [renal biopsies from patients with minimal change disease (C, F)], there was very slight staining for TWEAK and Fn14 in glomeruli, while intense staining was observed in renal tubular cells. Scale bar = 50 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25885587), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of TWEAK and Fn14 in renal biopsies from IgAN patients was examine. Immunohistochemistry for both TWEAK (A, B) and Fn14 (D, E) were detected in glomerular crescents (the areas delineated by the squares). In the controls [renal biopsies from patients with minimal change disease (C, F)], there was very slight staining for TWEAK and Fn14 in glomeruli, while intense staining was observed in renal tubular cells. Scale bar = 50 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25885587), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of TWEAK and Fn14 in renal biopsies from IgAN patients was examine. Immunohistochemistry for both TWEAK (A, B) and Fn14 (D, E) were detected in glomerular crescents (the areas delineated by the squares). In the controls [renal biopsies from patients with minimal change disease (C, F)], there was very slight staining for TWEAK and Fn14 in glomeruli, while intense staining was observed in renal tubular cells. Scale bar = 50 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25885587), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of TWEAK and Fn14 in renal biopsies from IgAN patients was examine. Immunohistochemistry for both TWEAK (A, B) and Fn14 (D, E) were detected in glomerular crescents (the areas delineated by the squares). In the controls [renal biopsies from patients with minimal change disease (C, F)], there was very slight staining for TWEAK and Fn14 in glomeruli, while intense staining was observed in renal tubular cells. Scale bar = 50 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25885587), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

TWEAK R/TNFRSF12 Antibody Summary

• Immunogen: recombinant human TWEAK R/TNFRSF12
  Glu28-Trp79
  Accession # Q9NP84
• Specificity: Detects human TWEAK R/TNFRSF12 in direct ELISAs and Western blots. In direct ELISAs, approximately 80% cross-reactivity with recombinant mouse TWEAK R/TNFRSF12 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TNFRSF12A
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.3-1.2 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TWEAK R/TNFRSF12 Antibody

• CD266 antigen
• CD266
• FGF-inducible 14
• Fibroblast growth factor-inducible immediate-early response protein 14
• Fn14
• FN14tumor necrosis factor receptor superfamily member 12A
• TNFRSF12
• TNFRSF12A
• tumor necrosis factor receptor superfamily, member 12A
• TWEAK R
• TWEAKR
• tweak-receptor
• type I transmembrane protein Fn14

Background

The gene for TNF-related weak inducer of apoptosis receptor (TWEAK R) was originally identified as a fibroblast growth factor-inducible immediate-early response gene Fn14 in mouse NIH 3T3 fibroblasts (1, 2). Human TWEAK R cDNA encodes a 129 amino acid (aa) residue type I transmembrane protein with a 27 aa signal peptide, a 53 aa extracellular domain, a 21 aa transmembrane domain and a 28 aa cytoplasmic domain (1-3). Human and mouse TWEAK R share 82% aa sequence identity. TWEAK R is the smallest member of the TNF receptor superfamily and contains only one cysteine-rich region in its extracellular domain. The TWEAK R cytoplasmic domain conatins one TRAF binding motif which binds TRAFs 1, 2, and 3. TWEAK R binds its ligand TWEAK/TNFSF12 with high affinity to initiate a signal transduction cascade that depending upon the cell type, may lead to a variety of cellular responses including cell death, cell proliferation, and angiogenesis (2-6). In new born mice, TWEAK R is highly expressed in all tissues examined (heart, intestine, kidney, liver, lung and skin) (1). In adult mice, high TWEAK R expression levels are found in the heart and ovary, while lower expression levels are detected in the lung, kidney, skin. Elevated levels of TWEAK R mRNA were found in human or mouse hepatocellular carcinoma specimens, in regenerating mouse liver and in injured rat arteries (2, 3).

1. Meighan-Mantha, R. et al. (1999) J. Biol. Chem. 274:33166.
2. Feng, S. et al. (2000) Am J. Pathol. 156:1253.
3. Wiley, S. et al. (2001) Immunity 15:837.
4. Schneider, P. et al. (1999) Eur. J. Immunol. 29:1785.
5. Nakayama, M. et al. (2002) J. Immunol. 168:734.
6. Lynch, C.N. et al. (1999) J. Biol. Chem. 274:8455.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TWEAK R/TNFRSF12 Antibody (AF1199)(3)

Publications using AF1199

• Fang Sun, Jian Teng, Pengfei Yu, Wenshuang Li, Jing Chang, Honglei Xu Involvement of TWEAK and the NF-kappa B signaling pathway in lupus nephritis Experimental and Therapeutic Medicine 1/5/2018 [PMID: 29456665]
• Sasaki Y, Shimizu Y, Suzuki Y, Horikoshi S, Tomino Y TWEAK/Fn14 system and crescent formation in IgA nephropathy. BMC Nephrol, 2015-03-14;16(0):27. 2015-03-14 [PMID: 25885587] (IHC-P, Human)
• Gaudineau B, Fougere M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion. J Cell Sci, 2012-07-05;125(0):4475-86. 2012-07-05 [PMID: 22767506] (Neutralization, Human)

Bioinformatics

• Gene Symbol: TNFRSF12A
• Uniprot:
  • Q9NP84()